Chairs
- Sibylle Loibl (Neu-Isenburg, Germany)
- Andrew Tutt (London, United Kingdom)
Which checkpoint inhibitor, in which biomarker sub-group and when: What is approved, what is coming and what are the trials telling us (ID 90)
Lecture Time
10:45 - 11:05
Speakers
- Sibylle Loibl (Neu-Isenburg, Germany)
Authors
- Sibylle Loibl (Neu-Isenburg, Germany)
How to improve outcomes in those non-pCR after NACT+CPI (ID 91)
Lecture Time
11:05 - 11:25
Speakers
- Sheeba Irshad (London, United Kingdom)
Authors
- Sheeba Irshad (London, United Kingdom)
PARP inhibition in early breast cancer: What have we learned and how can we move forward? (ID 92)
Lecture Time
11:25 - 11:45
Speakers
- Andrew Tutt (London, United Kingdom)
Authors
- Andrew Tutt (London, United Kingdom)
PARP inhibitor combination strategies in early breast cancer: Rationale and results to date (ID 93)
Lecture Time
11:45 - 12:05
Speakers
- Kevin Punie (Leuven, Belgium)
Authors
- Kevin Punie (Leuven, Belgium)
Q&A and discussion (ID 94)
Lecture Time
12:05 - 12:15
Speakers
- To be Announced (Barcelona, Spain)
Authors
- To be Announced (Barcelona, Spain)